sample_name,protocol,organism,read_type,data_source,srr,srx,sample_title,sample_geo_accession,sample_status,sample_submission_date,sample_last_update_date,sample_type,sample_channel_count,sample_source_name_ch1,sample_organism_ch1,sample_taxid_ch1,sample_characteristics_ch1,sample_molecule_ch1,sample_platform_id,sample_contact_name,sample_contact_email,sample_contact_address,sample_contact_city,sample_contact_zip_postal_code,sample_contact_country,sample_instrument_model,sample_library_selection,sample_library_source,sample_library_strategy,sample_supplementary_file_1,sample_series_id,sample_data_row_count,big_key,tissue,alternative_sample_id,tumor_type,gleason_score,pathological_t_stage,pathological_n_stage,assembly
prostate_tumor_rib0002854,,,,,,,Prostate_tumor_RIB0002854,GSM6788109,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 132.76386036961(total psa_(ng/ml,_pre-biopsy): 8.7(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788109/suppl/GSM6788109_RIB0002854-htseq_counts.txt.gz,GSE220095,0,GSM6788109,FFPE PCa biopsy,RIB0002854,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002858,,,,,,,Prostate_tumor_RIB0002858,GSM6788110,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 134.669404517454(total psa_(ng/ml,_pre-biopsy): 4.3(tumor cell_content_(%): 35",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788110/suppl/GSM6788110_RIB0002858-htseq_counts.txt.gz,GSE220095,0,GSM6788110,FFPE PCa biopsy,RIB0002858,Primary tumor,7=3+4,pT2c,pN1,GRCh38 (hg38)
prostate_tumor_rib0002830,,,,,,,Prostate_tumor_RIB0002830,GSM6788111,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 62.8172484599589(total psa_(ng/ml,_pre-biopsy): 22.35(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788111/suppl/GSM6788111_RIB0002830-htseq_counts.txt.gz,GSE220095,0,GSM6788111,FFPE PCa biopsy,RIB0002830,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002829,,,,,,,Prostate_tumor_RIB0002829,GSM6788112,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 2.43121149897331(total psa_(ng/ml,_pre-biopsy): 6.2(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788112/suppl/GSM6788112_RIB0002829-htseq_counts.txt.gz,GSE220095,0,GSM6788112,FFPE PCa biopsy,RIB0002829,Primary tumor,9=5+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0002853,,,,,,,Prostate_tumor_RIB0002853,GSM6788113,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 29.3716632443532(total psa_(ng/ml,_pre-biopsy): 9.77(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788113/suppl/GSM6788113_RIB0002853-htseq_counts.txt.gz,GSE220095,0,GSM6788113,FFPE PCa biopsy,RIB0002853,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002861,,,,,,,Prostate_tumor_RIB0002861,GSM6788114,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 130.924024640657(total psa_(ng/ml,_pre-biopsy): 7.87(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788114/suppl/GSM6788114_RIB0002861-htseq_counts.txt.gz,GSE220095,0,GSM6788114,FFPE PCa biopsy,RIB0002861,Primary tumor,7=3+4,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0002824,,,,,,,Prostate_tumor_RIB0002824,GSM6788115,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 38.8008213552361(total psa_(ng/ml,_pre-biopsy): 4.69(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788115/suppl/GSM6788115_RIB0002824-htseq_counts.txt.gz,GSE220095,0,GSM6788115,FFPE PCa biopsy,RIB0002824,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002892,,,,,,,Prostate_tumor_RIB0002892,GSM6788116,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 119.622176591376(total psa_(ng/ml,_pre-biopsy): 6.77(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788116/suppl/GSM6788116_RIB0002892-htseq_counts.txt.gz,GSE220095,0,GSM6788116,FFPE PCa biopsy,RIB0002892,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002549,,,,,,,Prostate_tumor_RIB0002549,GSM6788117,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 100.402464065708(total psa_(ng/ml,_pre-biopsy): 7.8(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788117/suppl/GSM6788117_RIB0002549-htseq_counts.txt.gz,GSE220095,0,GSM6788117,FFPE PCa biopsy,RIB0002549,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015798,,,,,,,Prostate_tumor_RIB0015798,GSM6788118,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 131.186858316222(total psa_(ng/ml,_pre-biopsy): 10.85(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788118/suppl/GSM6788118_RIB0015798-htseq_counts.txt.gz,GSE220095,0,GSM6788118,FFPE PCa biopsy,RIB0015798,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015745,,,,,,,Prostate_tumor_RIB0015745,GSM6788119,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 129.051334702259(total psa_(ng/ml,_pre-biopsy): 2.68(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788119/suppl/GSM6788119_RIB0015745-htseq_counts.txt.gz,GSE220095,0,GSM6788119,FFPE PCa biopsy,RIB0015745,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007100,,,,,,,Prostate_tumor_RIB0007100,GSM6788120,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 129.215605749487(total psa_(ng/ml,_pre-biopsy): 5(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788120/suppl/GSM6788120_RIB0007100-htseq_counts.txt.gz,GSE220095,0,GSM6788120,FFPE PCa biopsy,RIB0007100,Primary tumor,6=3+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0015774,,,,,,,Prostate_tumor_RIB0015774,GSM6788121,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 129.872689938398(total psa_(ng/ml,_pre-biopsy): 17.7(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788121/suppl/GSM6788121_RIB0015774-htseq_counts.txt.gz,GSE220095,0,GSM6788121,FFPE PCa biopsy,RIB0015774,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002507,,,,,,,Prostate_tumor_RIB0002507,GSM6788122,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 128.985626283368(total psa_(ng/ml,_pre-biopsy): 5.7(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788122/suppl/GSM6788122_RIB0002507-htseq_counts.txt.gz,GSE220095,0,GSM6788122,FFPE PCa biopsy,RIB0002507,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002577,,,,,,,Prostate_tumor_RIB0002577,GSM6788123,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 73.7577002053388(total psa_(ng/ml,_pre-biopsy): 6(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788123/suppl/GSM6788123_RIB0002577-htseq_counts.txt.gz,GSE220095,0,GSM6788123,FFPE PCa biopsy,RIB0002577,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002521,,,,,,,Prostate_tumor_RIB0002521,GSM6788124,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 123.137577002053(total psa_(ng/ml,_pre-biopsy): 8(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788124/suppl/GSM6788124_RIB0002521-htseq_counts.txt.gz,GSE220095,0,GSM6788124,FFPE PCa biopsy,RIB0002521,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0002506,,,,,,,Prostate_tumor_RIB0002506,GSM6788125,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 120.739219712526(total psa_(ng/ml,_pre-biopsy): 5.54(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788125/suppl/GSM6788125_RIB0002506-htseq_counts.txt.gz,GSE220095,0,GSM6788125,FFPE PCa biopsy,RIB0002506,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025491,,,,,,,Prostate_tumor_RIB0025491,GSM6788126,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 120.542094455852(total psa_(ng/ml,_pre-biopsy): 4.79(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788126/suppl/GSM6788126_RIB0025491-htseq_counts.txt.gz,GSE220095,0,GSM6788126,FFPE PCa biopsy,RIB0025491,Primary tumor,6=3+3,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0018085,,,,,,,Prostate_tumor_RIB0018085,GSM6788127,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 128.459958932238(total psa_(ng/ml,_pre-biopsy): 5.66(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788127/suppl/GSM6788127_RIB0018085-htseq_counts.txt.gz,GSE220095,0,GSM6788127,FFPE PCa biopsy,RIB0018085,Primary tumor,6=3+3,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0025447,,,,,,,Prostate_tumor_RIB0025447,GSM6788128,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 106.086242299795(total psa_(ng/ml,_pre-biopsy): 8.11(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788128/suppl/GSM6788128_RIB0025447-htseq_counts.txt.gz,GSE220095,0,GSM6788128,FFPE PCa biopsy,RIB0025447,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015792,,,,,,,Prostate_tumor_RIB0015792,GSM6788129,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 82.6283367556468(total psa_(ng/ml,_pre-biopsy): 12.1(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788129/suppl/GSM6788129_RIB0015792-htseq_counts.txt.gz,GSE220095,0,GSM6788129,FFPE PCa biopsy,RIB0015792,Primary tumor,7=3+4,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0025489,,,,,,,Prostate_tumor_RIB0025489,GSM6788130,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 126.915811088296(total psa_(ng/ml,_pre-biopsy): 4.56(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788130/suppl/GSM6788130_RIB0025489-htseq_counts.txt.gz,GSE220095,0,GSM6788130,FFPE PCa biopsy,RIB0025489,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025481,,,,,,,Prostate_tumor_RIB0025481,GSM6788131,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 127.671457905544(total psa_(ng/ml,_pre-biopsy): 29(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788131/suppl/GSM6788131_RIB0025481-htseq_counts.txt.gz,GSE220095,0,GSM6788131,FFPE PCa biopsy,RIB0025481,Primary tumor,7=4+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025500,,,,,,,Prostate_tumor_RIB0025500,GSM6788132,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 127.540041067762(total psa_(ng/ml,_pre-biopsy): 4.31(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788132/suppl/GSM6788132_RIB0025500-htseq_counts.txt.gz,GSE220095,0,GSM6788132,FFPE PCa biopsy,RIB0025500,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025439,,,,,,,Prostate_tumor_RIB0025439,GSM6788133,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 45.0759753593429(total psa_(ng/ml,_pre-biopsy): 4.95(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788133/suppl/GSM6788133_RIB0025439-htseq_counts.txt.gz,GSE220095,0,GSM6788133,FFPE PCa biopsy,RIB0025439,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025371,,,,,,,Prostate_tumor_RIB0025371,GSM6788134,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 124.616016427105(total psa_(ng/ml,_pre-biopsy): 9.6(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788134/suppl/GSM6788134_RIB0025371-htseq_counts.txt.gz,GSE220095,0,GSM6788134,FFPE PCa biopsy,RIB0025371,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025389,,,,,,,Prostate_tumor_RIB0025389,GSM6788135,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 16.2299794661191(total psa_(ng/ml,_pre-biopsy): 15.1(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788135/suppl/GSM6788135_RIB0025389-htseq_counts.txt.gz,GSE220095,0,GSM6788135,FFPE PCa biopsy,RIB0025389,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025393,,,,,,,Prostate_tumor_RIB0025393,GSM6788136,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 96.1314168377823(total psa_(ng/ml,_pre-biopsy): 6.1(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788136/suppl/GSM6788136_RIB0025393-htseq_counts.txt.gz,GSE220095,0,GSM6788136,FFPE PCa biopsy,RIB0025393,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025378,,,,,,,Prostate_tumor_RIB0025378,GSM6788137,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 123.926078028747(total psa_(ng/ml,_pre-biopsy): 12.96(tumor cell_content_(%): 25",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788137/suppl/GSM6788137_RIB0025378-htseq_counts.txt.gz,GSE220095,0,GSM6788137,FFPE PCa biopsy,RIB0025378,Primary tumor,7=3+4,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0025400,,,,,,,Prostate_tumor_RIB0025400,GSM6788138,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 46.3572895277207(total psa_(ng/ml,_pre-biopsy): 42.97(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788138/suppl/GSM6788138_RIB0025400-htseq_counts.txt.gz,GSE220095,0,GSM6788138,FFPE PCa biopsy,RIB0025400,Primary tumor,9=4+5,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0025394,,,,,,,Prostate_tumor_RIB0025394,GSM6788139,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 123.203285420945(total psa_(ng/ml,_pre-biopsy): 13.9(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788139/suppl/GSM6788139_RIB0025394-htseq_counts.txt.gz,GSE220095,0,GSM6788139,FFPE PCa biopsy,RIB0025394,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025374,,,,,,,Prostate_tumor_RIB0025374,GSM6788140,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 68.0739219712526(total psa_(ng/ml,_pre-biopsy): 12.2(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788140/suppl/GSM6788140_RIB0025374-htseq_counts.txt.gz,GSE220095,0,GSM6788140,FFPE PCa biopsy,RIB0025374,Primary tumor,7=4+3,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0025405,,,,,,,Prostate_tumor_RIB0025405,GSM6788141,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 22.8336755646817(total psa_(ng/ml,_pre-biopsy): 27.2(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788141/suppl/GSM6788141_RIB0025405-htseq_counts.txt.gz,GSE220095,0,GSM6788141,FFPE PCa biopsy,RIB0025405,Primary tumor,9=4+5,pT3a,pN1,GRCh38 (hg38)
prostate_tumor_rib0025421,,,,,,,Prostate_tumor_RIB0025421,GSM6788142,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 123.696098562628(total psa_(ng/ml,_pre-biopsy): 9.56(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788142/suppl/GSM6788142_RIB0025421-htseq_counts.txt.gz,GSE220095,0,GSM6788142,FFPE PCa biopsy,RIB0025421,Primary tumor,6=3+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025496,,,,,,,Prostate_tumor_RIB0025496,GSM6788143,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 122.907597535934(total psa_(ng/ml,_pre-biopsy): 5.81(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788143/suppl/GSM6788143_RIB0025496-htseq_counts.txt.gz,GSE220095,0,GSM6788143,FFPE PCa biopsy,RIB0025496,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025434,,,,,,,Prostate_tumor_RIB0025434,GSM6788144,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 97.8398357289528(total psa_(ng/ml,_pre-biopsy): 4.88(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788144/suppl/GSM6788144_RIB0025434-htseq_counts.txt.gz,GSE220095,0,GSM6788144,FFPE PCa biopsy,RIB0025434,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025482,,,,,,,Prostate_tumor_RIB0025482,GSM6788145,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 122.11909650924(total psa_(ng/ml,_pre-biopsy): 5.64(tumor cell_content_(%): 25",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788145/suppl/GSM6788145_RIB0025482-htseq_counts.txt.gz,GSE220095,0,GSM6788145,FFPE PCa biopsy,RIB0025482,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025414,,,,,,,Prostate_tumor_RIB0025414,GSM6788146,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 50.5626283367556(total psa_(ng/ml,_pre-biopsy): 7(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788146/suppl/GSM6788146_RIB0025414-htseq_counts.txt.gz,GSE220095,0,GSM6788146,FFPE PCa biopsy,RIB0025414,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025483,,,,,,,Prostate_tumor_RIB0025483,GSM6788147,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 120.772073921971(total psa_(ng/ml,_pre-biopsy): 5.01(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788147/suppl/GSM6788147_RIB0025483-htseq_counts.txt.gz,GSE220095,0,GSM6788147,FFPE PCa biopsy,RIB0025483,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025488,,,,,,,Prostate_tumor_RIB0025488,GSM6788148,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 121.790554414784(total psa_(ng/ml,_pre-biopsy): 19.61(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788148/suppl/GSM6788148_RIB0025488-htseq_counts.txt.gz,GSE220095,0,GSM6788148,FFPE PCa biopsy,RIB0025488,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0027090,,,,,,,Prostate_tumor_RIB0027090,GSM6788149,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 119.88501026694(total psa_(ng/ml,_pre-biopsy): 4.24(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788149/suppl/GSM6788149_RIB0027090-htseq_counts.txt.gz,GSE220095,0,GSM6788149,FFPE PCa biopsy,RIB0027090,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007074,,,,,,,Prostate_tumor_RIB0007074,GSM6788150,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 108.813141683778(total psa_(ng/ml,_pre-biopsy): 9.78(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788150/suppl/GSM6788150_RIB0007074-htseq_counts.txt.gz,GSE220095,0,GSM6788150,FFPE PCa biopsy,RIB0007074,Primary tumor,6=3+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0027085,,,,,,,Prostate_tumor_RIB0027085,GSM6788151,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 116.566735112936(total psa_(ng/ml,_pre-biopsy): 7.38(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788151/suppl/GSM6788151_RIB0027085-htseq_counts.txt.gz,GSE220095,0,GSM6788151,FFPE PCa biopsy,RIB0027085,Primary tumor,7=3+4,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0027058,,,,,,,Prostate_tumor_RIB0027058,GSM6788152,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 120.344969199179(total psa_(ng/ml,_pre-biopsy): 3.11(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788152/suppl/GSM6788152_RIB0027058-htseq_counts.txt.gz,GSE220095,0,GSM6788152,FFPE PCa biopsy,RIB0027058,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0027067,,,,,,,Prostate_tumor_RIB0027067,GSM6788153,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 120.016427104723(total psa_(ng/ml,_pre-biopsy): 2.09(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788153/suppl/GSM6788153_RIB0027067-htseq_counts.txt.gz,GSE220095,0,GSM6788153,FFPE PCa biopsy,RIB0027067,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0027099,,,,,,,Prostate_tumor_RIB0027099,GSM6788154,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 76.517453798768(total psa_(ng/ml,_pre-biopsy): 10.3(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788154/suppl/GSM6788154_RIB0027099-htseq_counts.txt.gz,GSE220095,0,GSM6788154,FFPE PCa biopsy,RIB0027099,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0027062,,,,,,,Prostate_tumor_RIB0027062,GSM6788155,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 118.373716632444(total psa_(ng/ml,_pre-biopsy): 6.2(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788155/suppl/GSM6788155_RIB0027062-htseq_counts.txt.gz,GSE220095,0,GSM6788155,FFPE PCa biopsy,RIB0027062,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0018090,,,,,,,Prostate_tumor_RIB0018090,GSM6788156,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 117.289527720739(total psa_(ng/ml,_pre-biopsy): 5(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788156/suppl/GSM6788156_RIB0018090-htseq_counts.txt.gz,GSE220095,0,GSM6788156,FFPE PCa biopsy,RIB0018090,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025368,,,,,,,Prostate_tumor_RIB0025368,GSM6788157,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 113.445585215606(total psa_(ng/ml,_pre-biopsy): 6.54(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788157/suppl/GSM6788157_RIB0025368-htseq_counts.txt.gz,GSE220095,0,GSM6788157,FFPE PCa biopsy,RIB0025368,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025344,,,,,,,Prostate_tumor_RIB0025344,GSM6788158,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 109.47022587269(total psa_(ng/ml,_pre-biopsy): 15.27(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788158/suppl/GSM6788158_RIB0025344-htseq_counts.txt.gz,GSE220095,0,GSM6788158,FFPE PCa biopsy,RIB0025344,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025388,,,,,,,Prostate_tumor_RIB0025388,GSM6788159,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 117.35523613963(total psa_(ng/ml,_pre-biopsy): 10.25(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788159/suppl/GSM6788159_RIB0025388-htseq_counts.txt.gz,GSE220095,0,GSM6788159,FFPE PCa biopsy,RIB0025388,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025336,,,,,,,Prostate_tumor_RIB0025336,GSM6788160,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 24.7063655030801(total psa_(ng/ml,_pre-biopsy): 40.05(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788160/suppl/GSM6788160_RIB0025336-htseq_counts.txt.gz,GSE220095,0,GSM6788160,FFPE PCa biopsy,RIB0025336,Primary tumor,7=4+3,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0025332,,,,,,,Prostate_tumor_RIB0025332,GSM6788161,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 116.829568788501(total psa_(ng/ml,_pre-biopsy): 8.5(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788161/suppl/GSM6788161_RIB0025332-htseq_counts.txt.gz,GSE220095,0,GSM6788161,FFPE PCa biopsy,RIB0025332,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025369,,,,,,,Prostate_tumor_RIB0025369,GSM6788162,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 117.519507186858(total psa_(ng/ml,_pre-biopsy): 5(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788162/suppl/GSM6788162_RIB0025369-htseq_counts.txt.gz,GSE220095,0,GSM6788162,FFPE PCa biopsy,RIB0025369,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025343,,,,,,,Prostate_tumor_RIB0025343,GSM6788163,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 116.23819301848(total psa_(ng/ml,_pre-biopsy): 9.31(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788163/suppl/GSM6788163_RIB0025343-htseq_counts.txt.gz,GSE220095,0,GSM6788163,FFPE PCa biopsy,RIB0025343,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007063,,,,,,,Prostate_tumor_RIB0007063,GSM6788164,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 115.778234086242(total psa_(ng/ml,_pre-biopsy): 10.32(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788164/suppl/GSM6788164_RIB0007063-htseq_counts.txt.gz,GSE220095,0,GSM6788164,FFPE PCa biopsy,RIB0007063,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0007011,,,,,,,Prostate_tumor_RIB0007011,GSM6788165,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 115.679671457906(total psa_(ng/ml,_pre-biopsy): 12.87(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788165/suppl/GSM6788165_RIB0007011-htseq_counts.txt.gz,GSE220095,0,GSM6788165,FFPE PCa biopsy,RIB0007011,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007059,,,,,,,Prostate_tumor_RIB0007059,GSM6788166,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 116.041067761807(total psa_(ng/ml,_pre-biopsy): 4.48(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788166/suppl/GSM6788166_RIB0007059-htseq_counts.txt.gz,GSE220095,0,GSM6788166,FFPE PCa biopsy,RIB0007059,Primary tumor,7=3+4,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0007072,,,,,,,Prostate_tumor_RIB0007072,GSM6788167,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 116.402464065708(total psa_(ng/ml,_pre-biopsy): 23.57(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788167/suppl/GSM6788167_RIB0007072-htseq_counts.txt.gz,GSE220095,0,GSM6788167,FFPE PCa biopsy,RIB0007072,Primary tumor,9=5+4,pT4,pN1,GRCh38 (hg38)
prostate_tumor_rib0007025,,,,,,,Prostate_tumor_RIB0007025,GSM6788168,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 69.1909650924025(total psa_(ng/ml,_pre-biopsy): 4.89(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788168/suppl/GSM6788168_RIB0007025-htseq_counts.txt.gz,GSE220095,0,GSM6788168,FFPE PCa biopsy,RIB0007025,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007048,,,,,,,Prostate_tumor_RIB0007048,GSM6788169,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 80.5256673511294(total psa_(ng/ml,_pre-biopsy): 5.9(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788169/suppl/GSM6788169_RIB0007048-htseq_counts.txt.gz,GSE220095,0,GSM6788169,FFPE PCa biopsy,RIB0007048,Primary tumor,8=4+4,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0007026,,,,,,,Prostate_tumor_RIB0007026,GSM6788170,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 114.956878850103(total psa_(ng/ml,_pre-biopsy): 1.31(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788170/suppl/GSM6788170_RIB0007026-htseq_counts.txt.gz,GSE220095,0,GSM6788170,FFPE PCa biopsy,RIB0007026,Primary tumor,6=3+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0007062,,,,,,,Prostate_tumor_RIB0007062,GSM6788171,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 116.402464065708(total psa_(ng/ml,_pre-biopsy): 6.3(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788171/suppl/GSM6788171_RIB0007062-htseq_counts.txt.gz,GSE220095,0,GSM6788171,FFPE PCa biopsy,RIB0007062,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025319,,,,,,,Prostate_tumor_RIB0025319,GSM6788172,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 114.562628336756(total psa_(ng/ml,_pre-biopsy): 6.83(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788172/suppl/GSM6788172_RIB0025319-htseq_counts.txt.gz,GSE220095,0,GSM6788172,FFPE PCa biopsy,RIB0025319,Primary tumor,7=3+4,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0007001,,,,,,,Prostate_tumor_RIB0007001,GSM6788173,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 114.069815195072(total psa_(ng/ml,_pre-biopsy): 5.69(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788173/suppl/GSM6788173_RIB0007001-htseq_counts.txt.gz,GSE220095,0,GSM6788173,FFPE PCa biopsy,RIB0007001,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007020,,,,,,,Prostate_tumor_RIB0007020,GSM6788174,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 113.478439425051(total psa_(ng/ml,_pre-biopsy): 40.9(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788174/suppl/GSM6788174_RIB0007020-htseq_counts.txt.gz,GSE220095,0,GSM6788174,FFPE PCa biopsy,RIB0007020,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0015718,,,,,,,Prostate_tumor_RIB0015718,GSM6788175,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 82.9240246406571(total psa_(ng/ml,_pre-biopsy): 9.6(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788175/suppl/GSM6788175_RIB0015718-htseq_counts.txt.gz,GSE220095,0,GSM6788175,FFPE PCa biopsy,RIB0015718,Primary tumor,9=5+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007028,,,,,,,Prostate_tumor_RIB0007028,GSM6788176,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 113.084188911704(total psa_(ng/ml,_pre-biopsy): 11(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788176/suppl/GSM6788176_RIB0007028-htseq_counts.txt.gz,GSE220095,0,GSM6788176,FFPE PCa biopsy,RIB0007028,Primary tumor,7=3+4,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0018049,,,,,,,Prostate_tumor_RIB0018049,GSM6788177,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 38.6036960985626(total psa_(ng/ml,_pre-biopsy): 76.79(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788177/suppl/GSM6788177_RIB0018049-htseq_counts.txt.gz,GSE220095,0,GSM6788177,FFPE PCa biopsy,RIB0018049,Primary tumor,7=4+3,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0025352,,,,,,,Prostate_tumor_RIB0025352,GSM6788178,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 103.622176591376(total psa_(ng/ml,_pre-biopsy): 19.45(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788178/suppl/GSM6788178_RIB0025352-htseq_counts.txt.gz,GSE220095,0,GSM6788178,FFPE PCa biopsy,RIB0025352,Primary tumor,7=4+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0007086,,,,,,,Prostate_tumor_RIB0007086,GSM6788179,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 30.8501026694045(total psa_(ng/ml,_pre-biopsy): 11.1(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788179/suppl/GSM6788179_RIB0007086-htseq_counts.txt.gz,GSE220095,0,GSM6788179,FFPE PCa biopsy,RIB0007086,Primary tumor,7=3+4,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0007018,,,,,,,Prostate_tumor_RIB0007018,GSM6788180,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 112.328542094456(total psa_(ng/ml,_pre-biopsy): 5.94(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788180/suppl/GSM6788180_RIB0007018-htseq_counts.txt.gz,GSE220095,0,GSM6788180,FFPE PCa biopsy,RIB0007018,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025323,,,,,,,Prostate_tumor_RIB0025323,GSM6788181,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 1.31416837782341(total psa_(ng/ml,_pre-biopsy): 38.56(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788181/suppl/GSM6788181_RIB0025323-htseq_counts.txt.gz,GSE220095,0,GSM6788181,FFPE PCa biopsy,RIB0025323,Primary tumor,7=4+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0007088,,,,,,,Prostate_tumor_RIB0007088,GSM6788182,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 110.028747433265(total psa_(ng/ml,_pre-biopsy): 4.86(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788182/suppl/GSM6788182_RIB0007088-htseq_counts.txt.gz,GSE220095,0,GSM6788182,FFPE PCa biopsy,RIB0007088,Primary tumor,7=3+4,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0015796,,,,,,,Prostate_tumor_RIB0015796,GSM6788183,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 110.06160164271(total psa_(ng/ml,_pre-biopsy): 3.64(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788183/suppl/GSM6788183_RIB0015796-htseq_counts.txt.gz,GSE220095,0,GSM6788183,FFPE PCa biopsy,RIB0015796,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007083,,,,,,,Prostate_tumor_RIB0007083,GSM6788184,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 110.225872689938(total psa_(ng/ml,_pre-biopsy): 13.6(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788184/suppl/GSM6788184_RIB0007083-htseq_counts.txt.gz,GSE220095,0,GSM6788184,FFPE PCa biopsy,RIB0007083,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0007044,,,,,,,Prostate_tumor_RIB0007044,GSM6788185,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 109.043121149897(total psa_(ng/ml,_pre-biopsy): 8.1(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788185/suppl/GSM6788185_RIB0007044-htseq_counts.txt.gz,GSE220095,0,GSM6788185,FFPE PCa biopsy,RIB0007044,Primary tumor,7=3+4,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0025441,,,,,,,Prostate_tumor_RIB0025441,GSM6788186,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 51.0225872689938(total psa_(ng/ml,_pre-biopsy): 8.33(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788186/suppl/GSM6788186_RIB0025441-htseq_counts.txt.gz,GSE220095,0,GSM6788186,FFPE PCa biopsy,RIB0025441,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025437,,,,,,,Prostate_tumor_RIB0025437,GSM6788187,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 50.9897330595483(total psa_(ng/ml,_pre-biopsy): 15.7(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788187/suppl/GSM6788187_RIB0025437-htseq_counts.txt.gz,GSE220095,0,GSM6788187,FFPE PCa biopsy,RIB0025437,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025476,,,,,,,Prostate_tumor_RIB0025476,GSM6788188,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 52.1067761806982(total psa_(ng/ml,_pre-biopsy): 4.62(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788188/suppl/GSM6788188_RIB0025476-htseq_counts.txt.gz,GSE220095,0,GSM6788188,FFPE PCa biopsy,RIB0025476,Primary tumor,9=5+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025490,,,,,,,Prostate_tumor_RIB0025490,GSM6788189,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 51.8110882956879(total psa_(ng/ml,_pre-biopsy): 21.59(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788189/suppl/GSM6788189_RIB0025490-htseq_counts.txt.gz,GSE220095,0,GSM6788189,FFPE PCa biopsy,RIB0025490,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025472,,,,,,,Prostate_tumor_RIB0025472,GSM6788190,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 52.6324435318275(total psa_(ng/ml,_pre-biopsy): 13.7(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788190/suppl/GSM6788190_RIB0025472-htseq_counts.txt.gz,GSE220095,0,GSM6788190,FFPE PCa biopsy,RIB0025472,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025484,,,,,,,Prostate_tumor_RIB0025484,GSM6788191,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 51.8439425051335(total psa_(ng/ml,_pre-biopsy): 18.5(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788191/suppl/GSM6788191_RIB0025484-htseq_counts.txt.gz,GSE220095,0,GSM6788191,FFPE PCa biopsy,RIB0025484,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025412,,,,,,,Prostate_tumor_RIB0025412,GSM6788192,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 0.657084188911704(total psa_(ng/ml,_pre-biopsy): 22(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788192/suppl/GSM6788192_RIB0025412-htseq_counts.txt.gz,GSE220095,0,GSM6788192,FFPE PCa biopsy,RIB0025412,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025463,,,,,,,Prostate_tumor_RIB0025463,GSM6788193,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 14.4229979466119(total psa_(ng/ml,_pre-biopsy): 22.46(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788193/suppl/GSM6788193_RIB0025463-htseq_counts.txt.gz,GSE220095,0,GSM6788193,FFPE PCa biopsy,RIB0025463,Primary tumor,7=4+3,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0025425,,,,,,,Prostate_tumor_RIB0025425,GSM6788194,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 52.6324435318275(total psa_(ng/ml,_pre-biopsy): 6.03(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788194/suppl/GSM6788194_RIB0025425-htseq_counts.txt.gz,GSE220095,0,GSM6788194,FFPE PCa biopsy,RIB0025425,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025404,,,,,,,Prostate_tumor_RIB0025404,GSM6788195,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 31.3757700205339(total psa_(ng/ml,_pre-biopsy): 7.01(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788195/suppl/GSM6788195_RIB0025404-htseq_counts.txt.gz,GSE220095,0,GSM6788195,FFPE PCa biopsy,RIB0025404,Primary tumor,7=4+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025497,,,,,,,Prostate_tumor_RIB0025497,GSM6788196,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 51.482546201232(total psa_(ng/ml,_pre-biopsy): 23.71(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788196/suppl/GSM6788196_RIB0025497-htseq_counts.txt.gz,GSE220095,0,GSM6788196,FFPE PCa biopsy,RIB0025497,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025461,,,,,,,Prostate_tumor_RIB0025461,GSM6788197,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 42.4147843942505(total psa_(ng/ml,_pre-biopsy): 18.1(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788197/suppl/GSM6788197_RIB0025461-htseq_counts.txt.gz,GSE220095,0,GSM6788197,FFPE PCa biopsy,RIB0025461,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025419,,,,,,,Prostate_tumor_RIB0025419,GSM6788198,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 53.5852156057495(total psa_(ng/ml,_pre-biopsy): 13.7(tumor cell_content_(%): 45",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788198/suppl/GSM6788198_RIB0025419-htseq_counts.txt.gz,GSE220095,0,GSM6788198,FFPE PCa biopsy,RIB0025419,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025427,,,,,,,Prostate_tumor_RIB0025427,GSM6788199,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 53.0595482546201(total psa_(ng/ml,_pre-biopsy): 8.04(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788199/suppl/GSM6788199_RIB0025427-htseq_counts.txt.gz,GSE220095,0,GSM6788199,FFPE PCa biopsy,RIB0025427,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025416,,,,,,,Prostate_tumor_RIB0025416,GSM6788200,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 53.4537987679671(total psa_(ng/ml,_pre-biopsy): 1.98(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788200/suppl/GSM6788200_RIB0025416-htseq_counts.txt.gz,GSE220095,0,GSM6788200,FFPE PCa biopsy,RIB0025416,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025444,,,,,,,Prostate_tumor_RIB0025444,GSM6788201,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 4.59958932238193(total psa_(ng/ml,_pre-biopsy): 9.57(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788201/suppl/GSM6788201_RIB0025444-htseq_counts.txt.gz,GSE220095,0,GSM6788201,FFPE PCa biopsy,RIB0025444,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025499,,,,,,,Prostate_tumor_RIB0025499,GSM6788202,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 52.3367556468172(total psa_(ng/ml,_pre-biopsy): 12.57(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788202/suppl/GSM6788202_RIB0025499-htseq_counts.txt.gz,GSE220095,0,GSM6788202,FFPE PCa biopsy,RIB0025499,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025479,,,,,,,Prostate_tumor_RIB0025479,GSM6788203,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 52.4681724845996(total psa_(ng/ml,_pre-biopsy): 25.51(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788203/suppl/GSM6788203_RIB0025479-htseq_counts.txt.gz,GSE220095,0,GSM6788203,FFPE PCa biopsy,RIB0025479,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025413,,,,,,,Prostate_tumor_RIB0025413,GSM6788204,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 56.1806981519507(total psa_(ng/ml,_pre-biopsy): 7.18(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788204/suppl/GSM6788204_RIB0025413-htseq_counts.txt.gz,GSE220095,0,GSM6788204,FFPE PCa biopsy,RIB0025413,Primary tumor,7=3+4,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0025440,,,,,,,Prostate_tumor_RIB0025440,GSM6788205,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 53.0595482546201(total psa_(ng/ml,_pre-biopsy): 18.91(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788205/suppl/GSM6788205_RIB0025440-htseq_counts.txt.gz,GSE220095,0,GSM6788205,FFPE PCa biopsy,RIB0025440,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025443,,,,,,,Prostate_tumor_RIB0025443,GSM6788206,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 54.6694045174538(total psa_(ng/ml,_pre-biopsy): 4.36(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788206/suppl/GSM6788206_RIB0025443-htseq_counts.txt.gz,GSE220095,0,GSM6788206,FFPE PCa biopsy,RIB0025443,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025424,,,,,,,Prostate_tumor_RIB0025424,GSM6788207,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 54.2422997946612(total psa_(ng/ml,_pre-biopsy): 8.99(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788207/suppl/GSM6788207_RIB0025424-htseq_counts.txt.gz,GSE220095,0,GSM6788207,FFPE PCa biopsy,RIB0025424,Primary tumor,8=4+4,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0018117,,,,,,,Prostate_tumor_RIB0018117,GSM6788208,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 71.2936344969199(total psa_(ng/ml,_pre-biopsy): 5.59(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788208/suppl/GSM6788208_RIB0018117-htseq_counts.txt.gz,GSE220095,0,GSM6788208,FFPE PCa biopsy,RIB0018117,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015779,,,,,,,Prostate_tumor_RIB0015779,GSM6788209,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 58.1519507186858(total psa_(ng/ml,_pre-biopsy): 8.36(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788209/suppl/GSM6788209_RIB0015779-htseq_counts.txt.gz,GSE220095,0,GSM6788209,FFPE PCa biopsy,RIB0015779,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025333,,,,,,,Prostate_tumor_RIB0025333,GSM6788210,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 8.34496919917864(total psa_(ng/ml,_pre-biopsy): 4.1(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788210/suppl/GSM6788210_RIB0025333-htseq_counts.txt.gz,GSE220095,0,GSM6788210,FFPE PCa biopsy,RIB0025333,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025328,,,,,,,Prostate_tumor_RIB0025328,GSM6788211,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 6.11088295687885(total psa_(ng/ml,_pre-biopsy): 6.44(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788211/suppl/GSM6788211_RIB0025328-htseq_counts.txt.gz,GSE220095,0,GSM6788211,FFPE PCa biopsy,RIB0025328,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0018142,,,,,,,Prostate_tumor_RIB0018142,GSM6788212,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 38.9979466119097(total psa_(ng/ml,_pre-biopsy): 22.3(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788212/suppl/GSM6788212_RIB0018142-htseq_counts.txt.gz,GSE220095,0,GSM6788212,FFPE PCa biopsy,RIB0018142,Primary tumor,7=3+4,pT4,pN1,GRCh38 (hg38)
prostate_tumor_rib0018200,,,,,,,Prostate_tumor_RIB0018200,GSM6788213,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 26.7104722792608(total psa_(ng/ml,_pre-biopsy): 7.75(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788213/suppl/GSM6788213_RIB0018200-htseq_counts.txt.gz,GSE220095,0,GSM6788213,FFPE PCa biopsy,RIB0018200,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0018167,,,,,,,Prostate_tumor_RIB0018167,GSM6788214,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 28.3860369609856(total psa_(ng/ml,_pre-biopsy): 6.6(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788214/suppl/GSM6788214_RIB0018167-htseq_counts.txt.gz,GSE220095,0,GSM6788214,FFPE PCa biopsy,RIB0018167,Primary tumor,7=4+3,pT4,pN0,GRCh38 (hg38)
prostate_tumor_rib0018164,,,,,,,Prostate_tumor_RIB0018164,GSM6788215,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 80.4928131416838(total psa_(ng/ml,_pre-biopsy): 7.78(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788215/suppl/GSM6788215_RIB0018164-htseq_counts.txt.gz,GSE220095,0,GSM6788215,FFPE PCa biopsy,RIB0018164,Primary tumor,6=3+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0018171,,,,,,,Prostate_tumor_RIB0018171,GSM6788216,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 65.5770020533881(total psa_(ng/ml,_pre-biopsy): 7.79(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788216/suppl/GSM6788216_RIB0018171-htseq_counts.txt.gz,GSE220095,0,GSM6788216,FFPE PCa biopsy,RIB0018171,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0018156,,,,,,,Prostate_tumor_RIB0018156,GSM6788217,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 89.1663244353183(total psa_(ng/ml,_pre-biopsy): 7.31(tumor cell_content_(%): 100",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788217/suppl/GSM6788217_RIB0018156-htseq_counts.txt.gz,GSE220095,0,GSM6788217,FFPE PCa biopsy,RIB0018156,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0018198,,,,,,,Prostate_tumor_RIB0018198,GSM6788218,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 25.0349075975359(total psa_(ng/ml,_pre-biopsy): 6.27(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788218/suppl/GSM6788218_RIB0018198-htseq_counts.txt.gz,GSE220095,0,GSM6788218,FFPE PCa biopsy,RIB0018198,Primary tumor,9=4+5,pT4,pN1,GRCh38 (hg38)
prostate_tumor_rib0007043,,,,,,,Prostate_tumor_RIB0007043,GSM6788219,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 22.0780287474333(total psa_(ng/ml,_pre-biopsy): 5.88(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788219/suppl/GSM6788219_RIB0007043-htseq_counts.txt.gz,GSE220095,0,GSM6788219,FFPE PCa biopsy,RIB0007043,Primary tumor,7=3+4,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0007090,,,,,,,Prostate_tumor_RIB0007090,GSM6788220,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 21.1581108829569(total psa_(ng/ml,_pre-biopsy): 20.01(tumor cell_content_(%): 5",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788220/suppl/GSM6788220_RIB0007090-htseq_counts.txt.gz,GSE220095,0,GSM6788220,FFPE PCa biopsy,RIB0007090,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025456,,,,,,,Prostate_tumor_RIB0025456,GSM6788221,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 15.1457905544148(total psa_(ng/ml,_pre-biopsy): 5.62(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788221/suppl/GSM6788221_RIB0025456-htseq_counts.txt.gz,GSE220095,0,GSM6788221,FFPE PCa biopsy,RIB0025456,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025349,,,,,,,Prostate_tumor_RIB0025349,GSM6788222,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 7.72073921971253(total psa_(ng/ml,_pre-biopsy): 11.7(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788222/suppl/GSM6788222_RIB0025349-htseq_counts.txt.gz,GSE220095,0,GSM6788222,FFPE PCa biopsy,RIB0025349,Primary tumor,9=4+5,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025348,,,,,,,Prostate_tumor_RIB0025348,GSM6788223,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 39.7207392197125(total psa_(ng/ml,_pre-biopsy): 1(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788223/suppl/GSM6788223_RIB0025348-htseq_counts.txt.gz,GSE220095,0,GSM6788223,FFPE PCa biopsy,RIB0025348,Primary tumor,8=4+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025358,,,,,,,Prostate_tumor_RIB0025358,GSM6788224,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 22.0780287474333(total psa_(ng/ml,_pre-biopsy): 29.5(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788224/suppl/GSM6788224_RIB0025358-htseq_counts.txt.gz,GSE220095,0,GSM6788224,FFPE PCa biopsy,RIB0025358,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025308,,,,,,,Prostate_tumor_RIB0025308,GSM6788225,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 84.2710472279261(total psa_(ng/ml,_pre-biopsy): 18.02(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788225/suppl/GSM6788225_RIB0025308-htseq_counts.txt.gz,GSE220095,0,GSM6788225,FFPE PCa biopsy,RIB0025308,Primary tumor,7=4+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025356,,,,,,,Prostate_tumor_RIB0025356,GSM6788226,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 46.1601642710472(total psa_(ng/ml,_pre-biopsy): 40.47(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788226/suppl/GSM6788226_RIB0025356-htseq_counts.txt.gz,GSE220095,0,GSM6788226,FFPE PCa biopsy,RIB0025356,Primary tumor,7=4+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0018152,,,,,,,Prostate_tumor_RIB0018152,GSM6788227,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 64.8870636550308(total psa_(ng/ml,_pre-biopsy): 12.39(tumor cell_content_(%): 25",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788227/suppl/GSM6788227_RIB0018152-htseq_counts.txt.gz,GSE220095,0,GSM6788227,FFPE PCa biopsy,RIB0018152,Primary tumor,8=4+4,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025357,,,,,,,Prostate_tumor_RIB0025357,GSM6788228,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 16.5585215605749(total psa_(ng/ml,_pre-biopsy): 12.13(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788228/suppl/GSM6788228_RIB0025357-htseq_counts.txt.gz,GSE220095,0,GSM6788228,FFPE PCa biopsy,RIB0025357,Primary tumor,9=5+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025301,,,,,,,Prostate_tumor_RIB0025301,GSM6788229,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 30.9158110882957(total psa_(ng/ml,_pre-biopsy): 8.6(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788229/suppl/GSM6788229_RIB0025301-htseq_counts.txt.gz,GSE220095,0,GSM6788229,FFPE PCa biopsy,RIB0025301,Primary tumor,7=4+3,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025382,,,,,,,Prostate_tumor_RIB0025382,GSM6788230,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 83.482546201232(total psa_(ng/ml,_pre-biopsy): 26.73(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788230/suppl/GSM6788230_RIB0025382-htseq_counts.txt.gz,GSE220095,0,GSM6788230,FFPE PCa biopsy,RIB0025382,Primary tumor,7=4+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025346,,,,,,,Prostate_tumor_RIB0025346,GSM6788231,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 49.6755646817248(total psa_(ng/ml,_pre-biopsy): 6.9(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788231/suppl/GSM6788231_RIB0025346-htseq_counts.txt.gz,GSE220095,0,GSM6788231,FFPE PCa biopsy,RIB0025346,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025331,,,,,,,Prostate_tumor_RIB0025331,GSM6788232,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 52.8952772073922(total psa_(ng/ml,_pre-biopsy): 15.05(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788232/suppl/GSM6788232_RIB0025331-htseq_counts.txt.gz,GSE220095,0,GSM6788232,FFPE PCa biopsy,RIB0025331,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015770,,,,,,,Prostate_tumor_RIB0015770,GSM6788233,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 54.735112936345(total psa_(ng/ml,_pre-biopsy): 20.6(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788233/suppl/GSM6788233_RIB0015770-htseq_counts.txt.gz,GSE220095,0,GSM6788233,FFPE PCa biopsy,RIB0015770,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025302,,,,,,,Prostate_tumor_RIB0025302,GSM6788234,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 77.9630390143737(total psa_(ng/ml,_pre-biopsy): 11.4(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788234/suppl/GSM6788234_RIB0025302-htseq_counts.txt.gz,GSE220095,0,GSM6788234,FFPE PCa biopsy,RIB0025302,Primary tumor,7=3+4,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0018135,,,,,,,Prostate_tumor_RIB0018135,GSM6788235,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 32.3613963039014(total psa_(ng/ml,_pre-biopsy): 15.57(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788235/suppl/GSM6788235_RIB0018135-htseq_counts.txt.gz,GSE220095,0,GSM6788235,FFPE PCa biopsy,RIB0018135,Primary tumor,7=3+4,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0018137,,,,,,,Prostate_tumor_RIB0018137,GSM6788236,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 21.4209445585216(total psa_(ng/ml,_pre-biopsy): 28.64(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788236/suppl/GSM6788236_RIB0018137-htseq_counts.txt.gz,GSE220095,0,GSM6788236,FFPE PCa biopsy,RIB0018137,Primary tumor,9=4+5,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0027342,,,,,,,Prostate_tumor_RIB0027342,GSM6788237,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 8.64065708418891(total psa_(ng/ml,_pre-biopsy): 22.36(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788237/suppl/GSM6788237_RIB0027342-htseq_counts.txt.gz,GSE220095,0,GSM6788237,FFPE PCa biopsy,RIB0027342,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025361,,,,,,,Prostate_tumor_RIB0025361,GSM6788238,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 20.0082135523614(total psa_(ng/ml,_pre-biopsy): 12.81(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788238/suppl/GSM6788238_RIB0025361-htseq_counts.txt.gz,GSE220095,0,GSM6788238,FFPE PCa biopsy,RIB0025361,Primary tumor,7=3+4,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025324,,,,,,,Prostate_tumor_RIB0025324,GSM6788239,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 8.08213552361396(total psa_(ng/ml,_pre-biopsy): 52.27(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788239/suppl/GSM6788239_RIB0025324-htseq_counts.txt.gz,GSE220095,0,GSM6788239,FFPE PCa biopsy,RIB0025324,Primary tumor,9=4+5,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025285,,,,,,,Prostate_tumor_RIB0025285,GSM6788240,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 12.0246406570842(total psa_(ng/ml,_pre-biopsy): 10.42(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788240/suppl/GSM6788240_RIB0025285-htseq_counts.txt.gz,GSE220095,0,GSM6788240,FFPE PCa biopsy,RIB0025285,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025271,,,,,,,Prostate_tumor_RIB0025271,GSM6788241,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 26.0862422997947(total psa_(ng/ml,_pre-biopsy): 21.22(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788241/suppl/GSM6788241_RIB0025271-htseq_counts.txt.gz,GSE220095,0,GSM6788241,FFPE PCa biopsy,RIB0025271,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0025247,,,,,,,Prostate_tumor_RIB0025247,GSM6788242,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 12.9445585215606(total psa_(ng/ml,_pre-biopsy): 68.58(tumor cell_content_(%): 25",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788242/suppl/GSM6788242_RIB0025247-htseq_counts.txt.gz,GSE220095,0,GSM6788242,FFPE PCa biopsy,RIB0025247,Primary tumor,7=4+3,pT3a,pN1,GRCh38 (hg38)
prostate_tumor_rib0025281,,,,,,,Prostate_tumor_RIB0025281,GSM6788243,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 11.2361396303901(total psa_(ng/ml,_pre-biopsy): 6.6(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788243/suppl/GSM6788243_RIB0025281-htseq_counts.txt.gz,GSE220095,0,GSM6788243,FFPE PCa biopsy,RIB0025281,Primary tumor,7=4+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0025284,,,,,,,Prostate_tumor_RIB0025284,GSM6788244,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 8.27926078028747(total psa_(ng/ml,_pre-biopsy): 28.44(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788244/suppl/GSM6788244_RIB0025284-htseq_counts.txt.gz,GSE220095,0,GSM6788244,FFPE PCa biopsy,RIB0025284,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0025403,,,,,,,Prostate_tumor_RIB0025403,GSM6788245,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 45.700205338809(total psa_(ng/ml,_pre-biopsy): 121(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788245/suppl/GSM6788245_RIB0025403-htseq_counts.txt.gz,GSE220095,0,GSM6788245,FFPE PCa biopsy,RIB0025403,Primary tumor,9=4+5,pT4,pN1,GRCh38 (hg38)
prostate_tumor_rib0025310,,,,,,,Prostate_tumor_RIB0025310,GSM6788246,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 27.564681724846(total psa_(ng/ml,_pre-biopsy): 1.18(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788246/suppl/GSM6788246_RIB0025310-htseq_counts.txt.gz,GSE220095,0,GSM6788246,FFPE PCa biopsy,RIB0025310,Primary tumor,9=4+5,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0018104,,,,,,,Prostate_tumor_RIB0018104,GSM6788247,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 35.3839835728953(total psa_(ng/ml,_pre-biopsy): 8.3(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788247/suppl/GSM6788247_RIB0018104-htseq_counts.txt.gz,GSE220095,0,GSM6788247,FFPE PCa biopsy,RIB0018104,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015804,,,,,,,Prostate_tumor_RIB0015804,GSM6788248,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 75.8932238193019(total psa_(ng/ml,_pre-biopsy): 12.3(tumor cell_content_(%): NA",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788248/suppl/GSM6788248_RIB0015804-htseq_counts.txt.gz,GSE220095,0,GSM6788248,FFPE PCa biopsy,RIB0015804,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0015807,,,,,,,Prostate_tumor_RIB0015807,GSM6788249,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 5.51950718685832(total psa_(ng/ml,_pre-biopsy): 9.4(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788249/suppl/GSM6788249_RIB0015807-htseq_counts.txt.gz,GSE220095,0,GSM6788249,FFPE PCa biopsy,RIB0015807,Primary tumor,7=3+4,pT2a,pN1,GRCh38 (hg38)
prostate_tumor_rib0015775,,,,,,,Prostate_tumor_RIB0015775,GSM6788250,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 115.318275154004(total psa_(ng/ml,_pre-biopsy): 7.4(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788250/suppl/GSM6788250_RIB0015775-htseq_counts.txt.gz,GSE220095,0,GSM6788250,FFPE PCa biopsy,RIB0015775,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015832,,,,,,,Prostate_tumor_RIB0015832,GSM6788251,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 49.5441478439425(total psa_(ng/ml,_pre-biopsy): 68.44(tumor cell_content_(%): NA",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788251/suppl/GSM6788251_RIB0015832-htseq_counts.txt.gz,GSE220095,0,GSM6788251,FFPE PCa biopsy,RIB0015832,Primary tumor,9=4+5,pT4,pN1,GRCh38 (hg38)
prostate_tumor_rib0015812,,,,,,,Prostate_tumor_RIB0015812,GSM6788252,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 110.948665297741(total psa_(ng/ml,_pre-biopsy): 5.39(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788252/suppl/GSM6788252_RIB0015812-htseq_counts.txt.gz,GSE220095,0,GSM6788252,FFPE PCa biopsy,RIB0015812,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015787,,,,,,,Prostate_tumor_RIB0015787,GSM6788253,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 80.5256673511294(total psa_(ng/ml,_pre-biopsy): 7.3(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788253/suppl/GSM6788253_RIB0015787-htseq_counts.txt.gz,GSE220095,0,GSM6788253,FFPE PCa biopsy,RIB0015787,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0015797,,,,,,,Prostate_tumor_RIB0015797,GSM6788254,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 2.92402464065708(total psa_(ng/ml,_pre-biopsy): 13.88(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788254/suppl/GSM6788254_RIB0015797-htseq_counts.txt.gz,GSE220095,0,GSM6788254,FFPE PCa biopsy,RIB0015797,Primary tumor,9=4+5,pT3b,pN0,GRCh38 (hg38)
prostate_tumor_rib0015736,,,,,,,Prostate_tumor_RIB0015736,GSM6788255,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): yes, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 62.652977412731(total psa_(ng/ml,_pre-biopsy): 8.2(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788255/suppl/GSM6788255_RIB0015736-htseq_counts.txt.gz,GSE220095,0,GSM6788255,FFPE PCa biopsy,RIB0015736,Primary tumor,7=4+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020771,,,,,,,Prostate_tumor_RIB0020771,GSM6788256,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 101.125256673511(total psa_(ng/ml,_pre-biopsy): 3.01(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788256/suppl/GSM6788256_RIB0020771-htseq_counts.txt.gz,GSE220095,0,GSM6788256,FFPE PCa biopsy,RIB0020771,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020703,,,,,,,Prostate_tumor_RIB0020703,GSM6788257,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 96.2299794661191(total psa_(ng/ml,_pre-biopsy): 5.16(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788257/suppl/GSM6788257_RIB0020703-htseq_counts.txt.gz,GSE220095,0,GSM6788257,FFPE PCa biopsy,RIB0020703,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020733,,,,,,,Prostate_tumor_RIB0020733,GSM6788258,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 103.655030800821(total psa_(ng/ml,_pre-biopsy): 5.22(tumor cell_content_(%): 60",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788258/suppl/GSM6788258_RIB0020733-htseq_counts.txt.gz,GSE220095,0,GSM6788258,FFPE PCa biopsy,RIB0020733,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020714,,,,,,,Prostate_tumor_RIB0020714,GSM6788259,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 98.2012320328542(total psa_(ng/ml,_pre-biopsy): 2.4(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788259/suppl/GSM6788259_RIB0020714-htseq_counts.txt.gz,GSE220095,0,GSM6788259,FFPE PCa biopsy,RIB0020714,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020701,,,,,,,Prostate_tumor_RIB0020701,GSM6788260,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 101.716632443532(total psa_(ng/ml,_pre-biopsy): 6.6(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788260/suppl/GSM6788260_RIB0020701-htseq_counts.txt.gz,GSE220095,0,GSM6788260,FFPE PCa biopsy,RIB0020701,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011824,,,,,,,Prostate_tumor_RIB0011824,GSM6788261,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 79.9342915811088(total psa_(ng/ml,_pre-biopsy): 29.33(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788261/suppl/GSM6788261_RIB0011824-htseq_counts.txt.gz,GSE220095,0,GSM6788261,FFPE PCa biopsy,RIB0011824,Primary tumor,10=5+5,pT3a,pN1,GRCh38 (hg38)
prostate_tumor_rib0020721,,,,,,,Prostate_tumor_RIB0020721,GSM6788262,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 74.2505133470226(total psa_(ng/ml,_pre-biopsy): 5.42(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788262/suppl/GSM6788262_RIB0020721-htseq_counts.txt.gz,GSE220095,0,GSM6788262,FFPE PCa biopsy,RIB0020721,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020772,,,,,,,Prostate_tumor_RIB0020772,GSM6788263,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 78.5215605749487(total psa_(ng/ml,_pre-biopsy): 4.05(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788263/suppl/GSM6788263_RIB0020772-htseq_counts.txt.gz,GSE220095,0,GSM6788263,FFPE PCa biopsy,RIB0020772,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020787,,,,,,,Prostate_tumor_RIB0020787,GSM6788264,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 78.5215605749487(total psa_(ng/ml,_pre-biopsy): 6.47(tumor cell_content_(%): 70",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788264/suppl/GSM6788264_RIB0020787-htseq_counts.txt.gz,GSE220095,0,GSM6788264,FFPE PCa biopsy,RIB0020787,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020775,,,,,,,Prostate_tumor_RIB0020775,GSM6788265,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 70.3737166324435(total psa_(ng/ml,_pre-biopsy): 9.68(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788265/suppl/GSM6788265_RIB0020775-htseq_counts.txt.gz,GSE220095,0,GSM6788265,FFPE PCa biopsy,RIB0020775,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0020725,,,,,,,Prostate_tumor_RIB0020725,GSM6788266,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 69.2238193018481(total psa_(ng/ml,_pre-biopsy): 14.5(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788266/suppl/GSM6788266_RIB0020725-htseq_counts.txt.gz,GSE220095,0,GSM6788266,FFPE PCa biopsy,RIB0020725,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011896,,,,,,,Prostate_tumor_RIB0011896,GSM6788267,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 44.1232032854209(total psa_(ng/ml,_pre-biopsy): 10.42(tumor cell_content_(%): 20",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788267/suppl/GSM6788267_RIB0011896-htseq_counts.txt.gz,GSE220095,0,GSM6788267,FFPE PCa biopsy,RIB0011896,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020759,,,,,,,Prostate_tumor_RIB0020759,GSM6788268,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 62.4229979466119(total psa_(ng/ml,_pre-biopsy): 4.47(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788268/suppl/GSM6788268_RIB0020759-htseq_counts.txt.gz,GSE220095,0,GSM6788268,FFPE PCa biopsy,RIB0020759,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020741,,,,,,,Prostate_tumor_RIB0020741,GSM6788269,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 68.041067761807(total psa_(ng/ml,_pre-biopsy): 29.86(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788269/suppl/GSM6788269_RIB0020741-htseq_counts.txt.gz,GSE220095,0,GSM6788269,FFPE PCa biopsy,RIB0020741,Primary tumor,6=3+3,pT3b,pN1,GRCh38 (hg38)
prostate_tumor_rib0020755,,,,,,,Prostate_tumor_RIB0020755,GSM6788270,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 64.394250513347(total psa_(ng/ml,_pre-biopsy): 4.69(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788270/suppl/GSM6788270_RIB0020755-htseq_counts.txt.gz,GSE220095,0,GSM6788270,FFPE PCa biopsy,RIB0020755,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0020748,,,,,,,Prostate_tumor_RIB0020748,GSM6788271,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 59.7618069815195(total psa_(ng/ml,_pre-biopsy): 11.41(tumor cell_content_(%): 100",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788271/suppl/GSM6788271_RIB0020748-htseq_counts.txt.gz,GSE220095,0,GSM6788271,FFPE PCa biopsy,RIB0020748,Primary tumor,7=3+4,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0020778,,,,,,,Prostate_tumor_RIB0020778,GSM6788272,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 60.3860369609856(total psa_(ng/ml,_pre-biopsy): 12.75(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788272/suppl/GSM6788272_RIB0020778-htseq_counts.txt.gz,GSE220095,0,GSM6788272,FFPE PCa biopsy,RIB0020778,Primary tumor,6=3+3,pT3a,pN0,GRCh38 (hg38)
prostate_tumor_rib0011832,,,,,,,Prostate_tumor_RIB0011832,GSM6788273,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 82.4640657084189(total psa_(ng/ml,_pre-biopsy): 4.87(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788273/suppl/GSM6788273_RIB0011832-htseq_counts.txt.gz,GSE220095,0,GSM6788273,FFPE PCa biopsy,RIB0011832,Primary tumor,7=3+4,pT2a,pN0,GRCh38 (hg38)
prostate_tumor_rib0011826,,,,,,,Prostate_tumor_RIB0011826,GSM6788274,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 92.2217659137577(total psa_(ng/ml,_pre-biopsy): 13.57(tumor cell_content_(%): 80",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788274/suppl/GSM6788274_RIB0011826-htseq_counts.txt.gz,GSE220095,0,GSM6788274,FFPE PCa biopsy,RIB0011826,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011815,,,,,,,Prostate_tumor_RIB0011815,GSM6788275,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 79.047227926078(total psa_(ng/ml,_pre-biopsy): 3.84(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788275/suppl/GSM6788275_RIB0011815-htseq_counts.txt.gz,GSE220095,0,GSM6788275,FFPE PCa biopsy,RIB0011815,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011895,,,,,,,Prostate_tumor_RIB0011895,GSM6788276,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 85.9137577002053(total psa_(ng/ml,_pre-biopsy): 4.96(tumor cell_content_(%): 25",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788276/suppl/GSM6788276_RIB0011895-htseq_counts.txt.gz,GSE220095,0,GSM6788276,FFPE PCa biopsy,RIB0011895,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011802,,,,,,,Prostate_tumor_RIB0011802,GSM6788277,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 90.1848049281314(total psa_(ng/ml,_pre-biopsy): 4.95(tumor cell_content_(%): 15",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788277/suppl/GSM6788277_RIB0011802-htseq_counts.txt.gz,GSE220095,0,GSM6788277,FFPE PCa biopsy,RIB0011802,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011835,,,,,,,Prostate_tumor_RIB0011835,GSM6788278,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 82.6283367556468(total psa_(ng/ml,_pre-biopsy): 4.15(tumor cell_content_(%): 30",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788278/suppl/GSM6788278_RIB0011835-htseq_counts.txt.gz,GSE220095,0,GSM6788278,FFPE PCa biopsy,RIB0011835,Primary tumor,7=3+4,pT2c,pNA,GRCh38 (hg38)
prostate_tumor_rib0011834,,,,,,,Prostate_tumor_RIB0011834,GSM6788279,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 79.5400410677618(total psa_(ng/ml,_pre-biopsy): 9.81(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788279/suppl/GSM6788279_RIB0011834-htseq_counts.txt.gz,GSE220095,0,GSM6788279,FFPE PCa biopsy,RIB0011834,Primary tumor,7=3+4,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011853,,,,,,,Prostate_tumor_RIB0011853,GSM6788280,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 86.5051334702259(total psa_(ng/ml,_pre-biopsy): 5.8(tumor cell_content_(%): 50",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788280/suppl/GSM6788280_RIB0011853-htseq_counts.txt.gz,GSE220095,0,GSM6788280,FFPE PCa biopsy,RIB0011853,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011873,,,,,,,Prostate_tumor_RIB0011873,GSM6788281,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 84.0739219712526(total psa_(ng/ml,_pre-biopsy): 5.38(tumor cell_content_(%): 90",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788281/suppl/GSM6788281_RIB0011873-htseq_counts.txt.gz,GSE220095,0,GSM6788281,FFPE PCa biopsy,RIB0011873,Primary tumor,8=5+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011717,,,,,,,Prostate_tumor_RIB0011717,GSM6788282,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 82.9240246406571(total psa_(ng/ml,_pre-biopsy): 5.65(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788282/suppl/GSM6788282_RIB0011717-htseq_counts.txt.gz,GSE220095,0,GSM6788282,FFPE PCa biopsy,RIB0011717,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011850,,,,,,,Prostate_tumor_RIB0011850,GSM6788283,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 57.3305954825462(total psa_(ng/ml,_pre-biopsy): 6.58(tumor cell_content_(%): 10",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788283/suppl/GSM6788283_RIB0011850-htseq_counts.txt.gz,GSE220095,0,GSM6788283,FFPE PCa biopsy,RIB0011850,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
prostate_tumor_rib0011803,,,,,,,Prostate_tumor_RIB0011803,GSM6788284,Public on Sep 08 2023,Dec 05 2022,Sep 08 2023,SRA,1,FFPE PCa biopsy,Homo sapiens,9606,"biochemical relapse_(bcr): no, time to_bcr_(month),_censored_at_last_follow-up,_if_no_bcr: 54.0451745379877(total psa_(ng/ml,_pre-biopsy): 5.35(tumor cell_content_(%): 40",total RNA,GPL16791,"Michael,,Rade",michael.rade@izi.fraunhofer.de,Perlickstr. 1,Leipzig,04103,Germany,Illumina HiSeq 2500,cDNA,transcriptomic,RNA-Seq,ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM6788nnn/GSM6788284/suppl/GSM6788284_RIB0011803-htseq_counts.txt.gz,GSE220095,0,GSM6788284,FFPE PCa biopsy,RIB0011803,Primary tumor,6=3+3,pT2c,pN0,GRCh38 (hg38)
